{"id":"e1a5a377-1319-400e-b97f-69a6ce515890","slug":"sni-17-540","title":"Endovascular intra-arterial infusion for cerebral glioblastoma","authors":["Habiba Abdullahi","Mayur Sharma","Ahmed M. Shahrabani","Samer S. Hoz"],"abstract":"## INTRODUCTION\nThe conventional therapies for glioblastoma (GBM) have limited therapeutic outcomes, so new treatment regimens are constantly being explored. Endovascular intra-arterial (IA) infusion for GBM is a promising novel therapeutic agent delivery procedure, but there is limited evidence-based research. The mechanism of IA infusion explored in clinical trials is mainly related to bypassing the blood–brain barrier (BBB) and the blood–brain tumor barrier, which represent an inherent challe","thumbnailUrl":"https://sni-digital-videos.s3.amazonaws.com/articles/sni-17-540/figures/SNI-17-540-t001.jpg","publishDate":"2026-09-25T00:00:00.000Z","doi":"10.25259/SNI_775_2026","categories":["Neuro-oncology","Letter to the Editor"],"fullTextUrl":"https://surgicalneurologyint.com/api/articles/e1a5a377-1319-400e-b97f-69a6ce515890/pdf"}